anti-GPC3 TCR T-cell therapy (TCR2 Therapeutics)

N/A

Report date: 2025/01/26 19:00:28

Base Information

Drug Nameanti-GPC3 TCR T-cell therapy (TCR2 Therapeutics)

Drug Alias NameN/A

ClassificationBiologics > Protein drugs > Recombinant proteinCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy

Mechanisms of ActionHuman leukocyte antigen modulatorsGlypican-3 modulators

TargetsGlypican-3Human leukocyte antigen

Therapy Area/IndicationsSolid tumours

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesTcr2 Therapeutics Inc

China Registration ClassN/A

Develop Information

Active CompaniesTcr2 Therapeutics Inc

Inactive CompaniesN/A

Active IndicationsSolid tumours

Inactive IndicationsN/A

Other Information

ATC CodeN/A